The vascular endothelium synthesizes and releases a spectrum of vasoactive substances like nitric oxide (NO) and endothelin (ET). In hypertension, the delicate balance of endothelium-derived factors is disturbed. ET acts as the natural counterpart to endothelium-derived NO, which exerts vasodilating, antithrombotic, and antiproliferative effects, and inhibits leukocyte-adhesion to the vascular wall. Besides its blood pressure rising effect also in man, ET induces vascular and myocardial hypertrophy, which are independent risk factors for cardiovascular morbidity and mortality. The derangement of endothelial function in hypertension is likely to be caused in part by genetic factors, but also due to elevated blood pressure itself. Due to its position between blood pressure and smooth muscle cells responsible for peripheral resistance, the endothelium is thought to be both target and mediator of arterial hypertension. Oxi-
Introduction
The vascular endothelium synthesizes and releases a spectrum of vasoactive substances and therefore plays a fundamental role in the basal and dynamic regulation of the circulation. 1 Due to its strategic anatomical position, the endothelium is constantly exposed to the different risk factors for atherosclerosis. This review will focus on the role of the vascular endothelium in arterial hypertension, a major risk factor for the development of cardiovascular disease.
Nitric oxide
Nitric oxide (NO)-originally described as endothelium-derived relaxing factor (EDRF)-is released from endothelial cells in response to shear stress produced by blood flow, and in response to activation of a variety of receptors ( Figure 1 ). [2] [3] [4] NO is a free radical gas with an in vivo half-life of a few seconds, which is readily able to cross biological membranes. 2, 5, 6 After diffusion from endothelial to vascular smooth muscle cells, NO increases intracellular cyclic guanosin-monophosphat (cGMP) concentrations by activation of the enzyme guanyl-Since there is a continuous basal release of NO which determines the tone of peripheral blood vessels, systemic inhibition of NO synthesis causes an increase in arterial blood pressure. [9] [10] [11] [12] [13] There are two types of NO synthases: a constitutive and an inducible isoform. The former, which is present in endothelial cells, is therefore called endothelial NO synthase (eNOS), the latter is an important inflammatory mediator released by macrophages in response to immunological stimuli.
14 NO has also antithrombogenic, antiproliferative, leukocyte-adhesion inhibiting effects, and influences myocardial contractility. 10, 13, 15, 16 
Nitric oxide in experimental hypertension
Endothelium-derived NO-mediated vascular relaxation is impaired in spontaneously hypertensive animals. [17] [18] [19] [20] Thus, the bioavailability of NO is reduced. Surprisingly, the NO pathway is paradoxically upregulated in the resistance circulation and the heart of spontaneously hypertensive rats (SHR). 21, 22 Adult SHR possess a higher activity of eNOS than their normotensive counterparts. 23 Very young pre-hypertensive SHR have, in contrast, Figure 1 Endothelium-derived vasoactive substances. Nitric oxide (NO) is released from endothelial cells in response to shear stress and to activation of a variety of receptors. NO exerts vasodilating and antiproliferative effects on smooth muscle cells and inhibits thrombocyte-aggregation and leukocyte-adhesion. Endothelin-1 (ET-1) exerts its major vascular effects-vasoconstriction and cell proliferation-through activation of specific ET A receptors on vascular smooth muscle cells. In contrast, endothelial ET B receptors mediate vasodilation via release of nitric oxide and prostacyclin. Additionally, ET B receptors in the lung were shown to be a major pathway for the clearance of ET-1 from plasma. ACE denotes angiotensin-converting enzyme; ACh, acetylcholine; AII, angiotensin II; AT 1 , angiotensin 1 recetor; BK, bradykinine; COX, cyclooxygenase; ECE, endothelin-converting enzyme; EDHF, endothelium-derived hyperpolarizing factor; ET A and ET B , endothelin A and B receptor; ET-1, endothelin-1; L-Arg, PGH 2 , prostaglandin H 2 ; PGI 2 , prostacyclin; S, serotoninergic receptor; Thr, thrombine; T, thromboxane receptor; TXA 2 , thromboxane; 5-HT, 5-hydroxytryptamine (serotonine). Modified from Lü scher and Noll. 231 lower eNOS activity than young normotensive rats without a genetic background for hypertension, indicating that the increased activity of eNOS in adult SHR is indeed related to hypertension ( Figure  2) . Moreover, the plasma concentrations of the oxidative product of NO metabolism, nitrate, are higher in hypertensive rats than in normotensive controls. 21 These results indicate that the basal release of NO is increased in hypertensive rats.
Thus, it appears that in SHR, there must be a factor blunting the haemodynamic effect of NO. 24 Indeed, NO production is increased in stroke-prone SHR (SHRSP), but bioavailability is reduced. 25 Direct in situ measurement of NO release by a por- Figure 2 Increased activity of constitutive nitric oxide synthase in cardiac endothelium of spontaneously hypertensive rats (SHR, black bars). Adult SHR possess a higher activity of constitutive nitric oxide synthase (NOS) than their normotensive counterparts (WystarKyoto rats, WKY; open bars). Very young pre-hypertensive SHR have, in contrast, lower constitutive NOS activity than the normotensive, indicating that the increased activity of NOS in adult SHR is indeed related to hypertension. Modified from Nava et al. 23 phyrinic microsensor in SHRSP confirmed that hypertension is associated with increased NO decomposition by superoxide anions, ie, free oxygen radicals ( Figure 3 ). 26 In other models of hypertension-ie, in Dahl saltsensitive rats, in two-kidney, one clip experimental hypertension, and in DOCA-salt hypertensive ratsendothelium-dependent relaxation is also impaired. [27] [28] [29] [30] [31] However, NO production by eNOS is rather reduced than upregulated in Dahl salt-sensitive rats (Figure 3) . 29, 32, 33 L-arginine, the substrate of NO production by eNOS, normalizes blood pressure and simultaneously increases urinary excretion of nitrate, the degradation product of NO, in Dahl salt- sensitive rats. [34] [35] [36] [37] Further mechanisms contribute to the pathogenesis of salt-sensitive hypertension, eg, decreased expression of endothelial endothelin B receptors, which mediate NO release, 30, 32, 38 and altered expression of the constitutive brain NOS as well as the inducible NOS isoform, possibly leading to alterations in renal sympathetic nervous activity and sodium handling.
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Nitric oxide in human hypertension
Endothelium-dependent vasodilation in response to acetylcholine is impaired in patients with arterial hypertension, both in the forearm circulation (Figure 4) , [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] as well as in the coronary vascular bed. 54, 55 Endothelium-dependent vasodilation in the N-labelled arginine, ie, the substrate for enzymatic production of nitric oxide. Urinary excretion of the metabolic oxidation product of nitric oxide, nitrate, is reduced in hypertensive patients compared to normotensive controls. These data show that whole-body NO production in patients with essential hypertension is diminished under basal conditions. Modified from Forte et al. 59 Journal of Human Hypertension human forearm and coronary vascular beds are strongly correlated. 56, 57 Basal NO activity is decreased in hypertensive patients. 58 Furthermore, urinary excretion of the metabolic oxidation product of NO, 15 N nitrate, after administration of 15 N-labelled arginine (ie, the substrate for the generation of NO) is reduced in hypertensive patients compared to normotensive controls ( Figure 4) . 59 Thus, whole-body NO production in patients with essential hypertension is diminished under basal conditions. In line with these findings, the vasoconstrictor response to L-NMMA, an inhibitor of NO synthesis, was significantly less in hypertensive patients compared with normotensives, whereas there was no difference in the response to noradrenaline, an endothelium-independent vaso-Journal of Human Hypertension constrictor, between hypertensives and normotensives. 58, 60 Normotensive offspring of hypertensive parents exhibit impaired endothelium-dependent vasodilation to acetylcholine. 61 In parallel to manifest hypertension, in normotensive offspring, vasoconstriction due to inhibition of NO synthesis is decreased. 62 Thus, derangement of endothelial function in hypertension is likely to be caused in part by genetic factors, and not just a consequence of elevated blood pressure (although the haemodynamic factor is an important contributor).
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Role of oxidative stress in hypertension
Oxidative stress plays an important role in the pathogenesis of hypertension ( Figure 5 ). Superoxide anion (O − 2 ), an oxygen radical, can scavenge NO to form peroxynitrite (ONOO − ) effectively reducing the bioavailability of endothelium-derived NO. 26, 64 In addition, O − 2 can act as a vasoconstrictor. [65] [66] [67] [68] Nicotinamide adenine dinucleotide (NADH) dehydrogenase, a mitochondrial enzyme of the respiratory chain, seems to be a major source of O − 2 .
69 Expression of NAD(P)H oxidase in human coronary artery smooth muscle cells is upregulated by pulsatile stretch, generating increased oxidative stress. 70 Another source of O − 2 is cyclooxygenase (COX). 71 In contrast, xanthine oxidase, another generator of superoxide anions, does not appear to play a significant role in essential hypertension. 70, 72 Paradoxically, NOS (ie, the NO generating enzyme) can also produce superoxide anions. [73] [74] [75] Production of O − 2 in stroke-prone SHR, an experi- Figure 5 Role of oxidative stress in the pathogenesis of endothelial dysfunction in hypertension. Superoxide anion, generated by angiotensin II-activated NAD(P)H oxidase, by dysfunctional nitric oxide synthase, and by cyclooxygenase, can scavenge the vasodilator nitric oxide to form the highly reactive peroxynitrite. Peroxynitrite can damage cell membranes and oxidize lipids. In addition, superoxide anion can act as a vasoconstrictor. ACE denotes angiotensin-converting enzyme; ACh, acetylcholine; AII, angiotensin II; AT 1 , angiotensin 1 receptor; BH 4 , tetrahydrobiopterine; BK, bradykinine; COX, cyclooxygenase; ECE, endothelin-converting enzyme; EDHF, endothelium-derived hyperpolarizing factor; ET A and ET B , endothelin A and B receptor; ET-1, endothelin-1; H 2 O 2 , hydrogen peroxide; LArg, L-arginine; NAD(P)H oxidase, nicotinamide adenine dinucleotide oxidase; ·O mental model of genetic hypertension, can be prevented by NOS inhibition. 75 Administration of exogenous tetrahydrobiopterin (BH 4 ), an essential cofactor for NOS, can reduce excess O − 2 in the aorta of stroke-prone SHR ( Figure 5) . 75 In pre-hypertensive SHR, the calcium ionophore A23187-stimulated (ie, a receptor-independent activator of NOS) production of O − 2 was significantly higher than in control rats. NO release was reduced in SHR aortas, with opposite results in the presence of exogenous BH 4 78 Depending on the relative concentrations of NO and SOD, there may be a propensity for superoxide to preferentially react with NO, resulting in decreased bioavailability of NO.
The gene for cytosolic SOD (ie, SOD1) is located on the 21q22.1 region of chromosome 21. 79 Therefore, patients with Down syndrome (trisomy 21) have an extra copy of the SOD gene. Because of gene dosage excess, their SOD activity is 50% greater than in the diploid population leading to reduced O − 2 levels. 80 Indeed, patients with Down's syndrome have lower blood pressure levels, indicating a major role for O − 2 in the regulation of arterial blood pressure. Furthermore, the normal age-associated increase of blood pressure is absent in patients with Down's syndrome. 81 
Angiotensin II, superoxide, and nitric oxide
The renin-angiotensin system plays a major role in hypertension (Figure 1) . 82 Apart from direct vasoconstrictor effects of angiotensin II (AII), there are important interactions between AII, oxygen radicals, and NO.
AII stimulates generation of O − 2 by increasing the expression of the NAD(P)H oxidase gene (p22phox) and increasing the activity of NAD(P)H oxidase. [83] [84] [85] [86] The vasoconstrictor effect of AII is enhanced in the absence of NO, and diminished during co-infusion of antioxidant vitamin C. 87 Thus, the vasoconstrictive effect of AII is modulated by reactive oxygen species, mainly O − 2 , and their interaction with endothelium-derived NO ( Figure 5 ). Furthermore, AII increases the production of endothelin (ET) in the blood vessel wall, which exerts vasoconstriction and induces proliferation of the vascular smooth muscle cells.
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Prostaglandins
Prostacyclin (PGI 2 ) is a further endothelium-derived relaxing factor, which is released in response to shear stress (Figure 1) .
3,89-91 PGI 2 is synthesized by COX from arachidonic acid.
92 PGI 2 increases intracellular cyclic adenosin monophosphate (cAMP) in smooth muscle cells and platelets. In contrast to NO, PGI 2 does not contribute to the maintenance of basal vascular tone of large conduit arteries. 11 Instead, its platelet inhibitory effects are most important. The synergistic effect of both PGI 2 and NO enhances the antiplatelet activity. 93 Depending on the animal model of hypertension and the vascular bed, endothelium-dependent contractions to acetylcholine, a muscarinic receptordependent stimulator of NO synthesis, have been documented (Figure 3 ). Since this response is inhibited by COX inhibitors and thromboxane receptor antagonists, the most likely contractile factors are thromboxane A 2 and prostaglandin H 2 . 94, 95 Interactions between COX products and NO have been demonstrated. 96 In hypertensive patients, indomethacin, a COX inhibitor, significantly increased the response to acetylcholine, an effect that could be blocked by confusion of L-NMMA, an inhibitor of NO synthesis. 97 Therefore, COX inhibition restores NO-mediated vasodilation in essential hypertension, suggesting that COX-dependent substances can impair NO bioavailability. COX is indeed a source of the NO-scavenger O 
Endothelium-derived hyperpolarizing factor
Inhibitors of the L-arginine pathway do not prevent all endothelium-dependent relaxations. 98 Since under these conditions vascular smooth muscle cells become hyperpolarized, an endotheliumdependent hyperpolarizing factor (EDHF) of unknown chemical structure has been proposed ( Figure 1) . 99, 100 There is evidence that a calciumdependent potassium channel on endothelial or smooth muscle cells is important in mediating endoJournal of Human Hypertension thelium-dependent hyperpolarization, a mechanism that is impaired in arterial hypertension. [101] [102] [103] Endothelium-dependent hyperpolarization, may also be involved in the compensation for the impaired NO-system in patients with essential hypertension.
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Endothelin
Over a decade ago, a novel vasoconstrictor peptide synthesized by vascular endothelial cells has been identified. 106, 107 The family of endothelins (ET) consists of three closely related peptides, ET-1, ET-2, and ET-3, which are converted by endothelinconverting enzymes (ECE) from 'big endothelins' originating from large preproendothelin peptides cleaved by endopeptidases. [108] [109] [110] [111] [112] The ET peptides are not only synthesized in vascular endothelial and smooth muscle cells, but also in neural, renal, pulmonal, and some circulatory cells holding the genes for endothelins. 113, 114 The chemical structure of the endothelins is closely related to neurotoxins (sarafotoxins) produced by scorpions and snakes. [115] [116] [117] Factors modulating the expression of ET-1 are shearstress, adrenaline, angiotensin II, thrombin, inflammatory cytokines (tumor necrosis factor-␣, interleukin-1 and -2), transforming growth factor-␤, and hypoxia. [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] ET-1 is metabolized by a neutral endopeptidase, which also cleaves natriuretic peptides. 131, 132 ET-1 exerts its major vascular effects-vasoconstriction and cell proliferation-through activation of specific ET A receptors on vascular smooth muscle cells (Figure 1) . [133] [134] [135] [136] [137] [138] In contrast, endothelial ET B receptors mediate vasodilation via release of nitric oxide and prostacyclin. [139] [140] [141] Additionally, ET B receptors in the lung were shown to be a major pathway for the clearance of ET-1 from plasma. [142] [143] [144] [145] ET receptors are coupled to intracellular G proteins. The binding of ET-1 to its receptor causes activation of phospholipase C and the formation of inositoltriphosphate and diacylglycerol. The result is the release of calcium from the sarcoplasmatic reticulum and the entry of extracellular calcium by dihydropyridine-sensitive voltage channels, leading to increased intracellular calcium concentrations. 146, 147 This explains why ET-1-induced vasoconstriction is reversed by calcium channel blockers. [148] [149] [150] [151] ET-1 rather acts in a paracrine than an endocrine mode of action, which is reflected by plasma levels of ET-1 in the picomolar range. 152, 153 Infusion of an ET receptor antagonist into the brachial artery or systemically in healthy humans leads to vasodilation indicating a role of ET-1 in the maintenance of basal vascular tone. 154, 155 When ET-1 itself is infused, vasoconstriction follows a brief phase of vasodilation, which may be explained by relaxation of smooth muscle cells caused by ET B receptormediated release of the vasodilators nitric oxide and prostacyclin (Figure 1) . Additionally, ET-1 may also exert effects on the central and autonomic nervous system and alter baroreflex function. 148, 149, [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] In the kidney, sodium reabsorption is modulated. 166 
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Endothelin and endothelin antagonists in hypertension
Imbalance of endothelium-derived relaxing and contracting substances disturbs the normal function of the vascular endothelium. 1, 167 Endothelin acts as the natural counterpart to endothelium-derived NO, which exerts vasodilating, antithrombotic, and antiproliferative effects, and inhibits leukocyteadhesion to the vascular wall. 118 In addition to its arterial blood pressure rising effect in man, 168, 169 ET-1 induces vascular and myocardial hypertrophy, [170] [171] [172] which are independent risk factors for cardiovascular morbidity and mortality. [173] [174] [175] Indeed, in patients with essential hypertension, carotid wall thickening and left ventricular mass correlate with reduced endothelium-dependent vasodilation. 176, 177 The ET system is activated in several but not all animal models of arterial hypertension. 171, [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] Correspondingly, ET plasma levels have been reported to be elevated in certain patients with essential hypertension, 188 but this is a subject to controversy. 60, 189 The causal role of ET-1 in the pathogenesis of hypertension thus remains unclear. 190 However, because most ET-1 synthesized in endothelial cells is secreted abluminally, it might attain a higher concentration in the vessel wall than in plasma. Indeed, significant correlations between the amount of immunoreactive ET-1 in the tunica media and blood pressure, total serum cholesterol, and number of atherosclerotic sites were found. 191 In blood vessels of healthy controls, ET-1 was detectable almost exclusively in endothelial cells, whereas in patients with coronary artery disease and/or arterial hypertension, sizeable amounts of ET-1 were detectable in the tunica media of different types of arteries. 191 Furthermore, there is evidence that certain gene polymorphisms of ET-1 and ET receptors could be associated with blood pressure levels. [192] [193] [194] [195] Moreover, in hypertensive patients, TAK-044, a mixed ET A/B receptor antagonist, caused a significantly greater vasodilation than in normotensive subjects. 60 Since in this study plasma levels of ET-1 were similar in normo-and hypertensive patients, increased sensitivity to endogenous ET-1 has to be postulated. Decreased bioavailability of No may be involved in this phenomenon, since NO antagonizes some of the effects of ET-1.
Experimentally, endothelial dysfunction is ameliorated by treatment with an ET receptor antagonist in rats with AII-induced and chronic NO-deficient hypertension. 196, 197 Furthermore, ET receptor antagonism prevents vascular hypertrophy in a variety of other experimental models of hypertension (deoxycorticosterone acetate (DOCA)-salt hypertensive rats, DOCA salt-treated SHR, Dahl salt-sensitive rats, and stroke-prone SHR). 88, 181, [198] [199] [200] Similarly, treatment with a selective ET A receptor antagonist is able to attenuate the development of left ventricular hypertrophy in renovascular hypertensive rats. 201 Therefore, ET receptor antagonism may open new powerful therapeutic options in the treatment of hypertension and its clinical sequelae.
Bosentan, a mixed ET A/B receptor antagonist, decreases arterial blood pressure in patients with essential hypertension (Figure 6 ). 202 This effect did not provoke any neurohormonal activation, as reflected by a lack of increase in heart rate, plasma catecholamines, plasma renin activity, and plasma All levels. Further trials are needed to clarify if ET receptor antagonists offer additional benefits over conventional antihypertensive drugs.
Effects of antihypertensive therapy on endothelial function in hypertensive patients
In hypertensive animals, most classes of antihypertensive drugs (eg, calcium-channel blockers, ACEinhibitors, AT 1 receptor antagonists) improve endothelium-dependent vasodilation. 104, [203] [204] [205] [206] [207] [208] [209] Surprisingly and in contrast to animal experiments, antihypertensive therapy cannot consistently restore impaired endothelium-dependent vasodilation in patients with arterial hypertension. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] 210 However, depending on the antihypertensive drug and its pharmacological profile, improvements in endothelium-dependent vasodilation can be achieved (Table 1) . 45, 47, 49, [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] The multifactorial aetiology of essential hypertension as well as the duration of blood pressure elevation may explain certain inconsistent results of different investigators. 222, 223 Besides certain ACE-inhibitors, several calcium channel blocking agents were successful in improving endothelial function in human hypertension (Table 1) . Antioxidative properties of an antihypertensive drug are important, since oxidative stress plays a central role in the pathophysiology of human hypertension. Endothelial function of patients with hypertension is improved by ascorbic acid, an antioxidant vitamin, which restores the imbalance of increased NO decomposition by superoxide. 224 Scavenging of reactive oxygen species by antioxidants may become an important therapeutic strategy, 26, 225 since chronic treatment with vitamin C is in fact able to lower blood pressure in patients with hypertension. 226 Treatment with candesartan, an AT 1 receptor antagonist, reduced the vasodilator response to the mixed ET A/B receptor antagonist TAK-044 that was initially more pronounced in hypertensive patients than in normotensive controls. 216 This was paralleled by a reduction in circulating plasma ET-1 levels. Furthermore, the impaired vasoconstrictor response to L-NMMA, an inhibitor of NO synthesis, was augmented by antihypertensive treatment in hypertensives. Thus, the AII receptor blocker candesartan improves tonic NO release and reduces vasoconstriction to endogenous ET-1 in the forearm of hypertensive patients.
Interestingly, infusion of nebivolol, but not other beta-blockers, intra-arterially in the forearm of healthy subjects is associated with an increase in forearm blood flow. 227 The increase in forearm blood flow achieved by nebivolol can be prevented by coinfusion of the NO synthesis inhibitor L-NMMA. Similar results have been obtained in the human venous circulation. 228 This strongly suggests that nebivolol stimulates the formation of NO in the vas- Figure 6 Effects of bosentan, a mixed endothelin A/B receptor antagonist, on arterial blood pressure in patients with essential hypertension. As compared with placebo, treatment with bosentan resulted in a significant reduction in diastolic pressure with a daily dose of 500 or 2000 mg (an absolute reduction of 5.7 mm Hg at each dose), which was similar to the reduction with enalapril (5.8 mm Hg). There were no significant changes in heart rate. Bosentan did not result in activation of the sympathetic nervous system (as determined by measurement of the plasma noradrenaline level) or the renin-angiotensin system (as determined by measurements of plasma renin activity and angiotensin II levels). Modified from Krum et al. 49 
Potassium
Acute ACh Yes AII denotes angiotensin II; ACE, angiotensin-converting enzyme; ACh, acetylcholine; Bk, bradykinin; Ca, calcium; L-NMMA, N G -monomethyl-L-arginine; MCh, methacholine; and NO, nitric oxide. *This effect was paralleled by an enhanced endothelium-independent vasodilation to dosium nitroprusside. culature and may therefore have an interesting haemodynamic profile which leads-unlike other beta-blockers-to peripheral vasodilation in addition to the classical beta-blocking effects on the sympathetic nervous system, heart rate and cardiac
Journal of Human Hypertension contractility. 229, 230 Indeed, nebivolol also causes NO-dependent vasodilation in hypertensive patients. 217 It is currently not known if this favourable effect lasts during chronic treatment with this new type of ␤ 1 -blocker.
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The effects of newer antihypertensive agents-eg, ET receptor antagonists, ECE inhibitors, and inhibitors of neutral endopeptidases cleaving natriuretic peptides-on endothelial function in hypertension have to be awaited.
Conclusions
The vascular endothelium, synthesizing and releasing vasoactive substances, plays a crucial role in the pathogenesis of hypertension. Due to its position between blood pressure and smooth muscle cells responsible for peripheral resistance, the endothelium is thought to be both victim and offender in arterial hypertension. The delicate balance of endothelium-derived factors, which is disturbed in hypertension, can be restored by specific antihypertensive and antioxidant treatment.
